NCT02488902View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum

PHASE2CompletedINTERVENTIONAL
Enrollment

521

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

September 30, 1998

Study Completion Date

March 31, 2003

Conditions
Malaria
Interventions
DRUG

Placebo

Placebo

DRUG

Tafenoquine 25mg

Tafenoquine 25mg

DRUG

Tafenoquine 50mg

Tafenoquine 50mg

DRUG

Tafenoquine 100 mg

Tafenoquine 100 mg

DRUG

Tafenoquine 200 mg

Tafenoquine 200 mg

DRUG

Mefloquine 250 mg

Mefloquine 250 mg

Sponsors

Collaborators (1)

SmithKline Beecham
All Listed Sponsors
collaborator

SmithKline Beecham

INDUSTRY

lead

U.S. Army Medical Research and Development Command

FED

NCT02488902 - A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum | Biotech Hunter | Biotech Hunter